DEVELOPMENT OF ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISAS) FOR NINDS NIH BLUEPRINT NEUROTHERAPEUTICS (BPN) BIOLOGICS PROJECT

国家神经疾病和中风研究所(NINDS)，通过其蓝图(BPNBiologics) 网络，正在资助一项开发抗体的合作协议 治疗杜氏肌无力 营养不良(DMD)。BPN-Biologics合作协议的目标是优化 铅抗体，评价优化后铅的体内短期疗效 抗体，完成临床前研究和制造，并推动临床领先 通过IND使能研究和IND监管申报获得候选抗体。单人间 然后，向下选择具有最佳特性的先导子代抗体 体内和体外IND研究和临床试验评估的进展。

The National Institute of Neurological Disorders and Stroke (NINDS), via its Blueprint (BPNBiologics) network, is funding a cooperative agreement for the development of an antibody for treatment of Duchenne’s muscular dystrophy (DMD). The goals of the BPN-Biologics cooperative agreement are to optimize the lead antibody, evaluate short-term in vivo efficacy of the optimized lead antibody(ies), complete pre-clinical studies and manufacturing, and progress the lead clinical candidate antibody(ies) through IND-enabling studies and an IND regulatory filing. A single down-selected lead progeny antibody with optimal characteristics will then progress to IND-enabling in vivo and in vitro studies and to clinical trial evaluation.